Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | KMT2A |
| Variant | mutant |
| Impact List | unknown |
| Protein Effect | unknown |
| Gene Variant Descriptions | KMT2A mutant indicates an unspecified mutation in the KMT2A gene. |
| Associated Drug Resistance | |
| Category Variants Paths |
KMT2A mutant |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04811560 | Phase Ib/II | Bleximenib | A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) (cAMeLot-1) | Recruiting | USA | ISR | GBR | FRA | ESP | CAN | BRA | AUS | 4 |
| NCT05521087 | Phase I | Bleximenib + Cytarabine + Dexamethasone + Fludarabine + Pegaspargase + Vincristine Sulfate | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | Withdrawn | 0 | |
| NCT05453903 | Phase I | Bleximenib + Venetoclax Azacitidine + Bleximenib + Venetoclax Azacitidine + Bleximenib | A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 0 |